MannKind (STU:NNFN) Change In Payables And Accrued Expense : €-4.8 Mil (TTM As of Dec. 2024)

View and export this data going back to . Start your Free Trial

What is MannKind Change In Payables And Accrued Expense?

MannKind's Change In Payables And Accrued Expense for the quarter that ended in Dec. 2024 was €2.3 Mil. It means MannKind's Accounts Payable & Accrued Expense increased by €2.3 Mil from Sep. 2024 to Dec. 2024 .

MannKind's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2024 was €-5.2 Mil. It means MannKind's Accounts Payable & Accrued Expense declined by €5.2 Mil from Dec. 2023 to Dec. 2024 .

MannKind Change In Payables And Accrued Expense Historical Data

The historical data trend for MannKind's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MannKind Change In Payables And Accrued Expense Chart

MannKind Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

3.40

4.66

3.18

4.71

-5.24

MannKind Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															2.99	-1.62	-0.02	-5.55	2.34

MannKind Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-4.8 Mil.

MannKind Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of MannKind's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

MannKind Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MannKind Corp (STU:NNFN) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

MNKD:USA NNFN:Germany

Address

1 Casper Street, Danbury, CT, USA, 06810

Website

https://www.mannkindcorp.com

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.

MannKind Headlines

No Headlines